Global Generic and Biosimilar Pharmaceuticals Market Size, Share and Trends Analysis Report, By Type (Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, and Vaccines), By Application (Tumor, Diabetes, Cardiovascular, and Hemophilia), Forecast (2022-2028)

The global generic and biosimilar pharmaceuticals market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). As biologic medicines, biosimilars are inherently different from generics due to their molecular size and structure, and the complexity and cost of their development. A generic medicine is defined as a pharmaceutical product that has the same qualitative and quantitative composition in active substances and the same pharmaceutical form. Biosimilar medication was developed for many diseases including chronic diseases such as cancer, CVD, and many more.

The market is segmented based on the type and application. Based on the type, the market is sub-segmented into monoclonal antibodies, interferon, erythropoietin, insulin, and vaccines. Monoclonal antibodies require patients’ bodies to fight against the invader’s antigens. These cloned or duplicate antibodies are called monoclonal antibodies. Interferon is a natural substance that supports the body to fight against the immune system and other diseases, such as cancer. Erythropoietin is a substance that is naturally produced by the kidneys, and that stimulates the bone marrow to make red blood cells. Insulin is a hormone that supports to control body’s blood sugar level and metabolism. A vaccine is a preparation that is used to stimulate the body’s immune response against diseases.

Some major players in the market include Teva Pharmaceutical Industries Ltd., Novartis International AG, and Mylan NV, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, In October 2020, Ligand Pharmaceuticals announced its plan to acquire Pfenex to expand its product portfolios and capabilities. Additionally, Cinfa Biotech is a Spanish biotechnology company that focuses on the development of biosimilars.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Teva Pharmaceutical Industries Ltd., Novartis International AG, and Mylan NV, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?

Global Generic and Biosimilar Pharmaceuticals Market Report by Segment

By Type

• Monoclonal Antibodies
• Interferon
• Erythropoietin
• Insulin
• Vaccines

By Application

• Tumor
• Diabetes
• Cardiovascular
• Hemophilia

Global Generic and Biosimilar Pharmaceuticals Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa